<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04233112</url>
  </required_header>
  <id_info>
    <org_study_id>2019/08/15</org_study_id>
    <nct_id>NCT04233112</nct_id>
  </id_info>
  <brief_title>Melatonin and Osteogenic Loading on Bone Health on Osteopenia</brief_title>
  <acronym>MelaOstrong</acronym>
  <official_title>Assessing the Efficacy of Melatonin and Osteogenic Loading on Bone Health in an Osteopenic Population: MelaOstrong Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duquesne University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>OsteoStrong</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Duquesne University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be assessing the efficacy of melatonin and/or osteogenic loading on
      modulating bone health in an osteopenic population.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 26, 2020</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bone mineral density</measure>
    <time_frame>O-12 months</time_frame>
    <description>BMD at baseline (month 0) and month 12. Bone density will be assessed by DXA scan at baseline (month 0) and at month 12. Bone density, expressed as percentage change from baseline (T-scores), will be compared within and between groups at 12 mos.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Osteopenia</condition>
  <arm_group>
    <arm_group_label>Placebo/Mock</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsules; mock osteogenic loading</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Melatonin/Mock</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Melatonin capsules; mock osteogenic loading</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo/Osteogenic loading</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo capsules/osteogenic loading</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Melatonin/Osteogenic loading</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Melatonin capsules/osteogenic loading</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melatonin 5 mg</intervention_name>
    <description>Capsules containing 5mg melatonin will be prepared by Delta Care RX™ Pharmacy. Participants will be asked to take them nightly for one year.</description>
    <arm_group_label>Melatonin/Mock</arm_group_label>
    <arm_group_label>Melatonin/Osteogenic loading</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Osteogenic loading</intervention_name>
    <description>Osteogenic loading device therapy includes the emulation of impact forces through kinetic chains of natural impact absorption with fixtures that have the ability to capture bone compression data. Participants will be asked to perform osteogenic loading once per week.</description>
    <arm_group_label>Melatonin/Osteogenic loading</arm_group_label>
    <arm_group_label>Placebo/Osteogenic loading</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Mock for Osteogenic Loading</intervention_name>
    <description>Mock osteogenic loading will occur using the osteogenic loading device therapy includes the emulation of impact forces through kinetic chains of natural impact absorption with fixtures that have the ability to capture bone compression data. Participants will be asked to perform mock osteogenic loading once per week.</description>
    <arm_group_label>Melatonin/Mock</arm_group_label>
    <arm_group_label>Placebo/Mock</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (plant fiber) for melatonin</intervention_name>
    <description>Capsules containing plant fiber will be prepared by Delta Care RX™ Pharmacy. Participants will be asked to take them nightly for one year.</description>
    <arm_group_label>Placebo/Mock</arm_group_label>
    <arm_group_label>Placebo/Osteogenic loading</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria: To be included in the study, the participant must be a male or female
        with osteopenia (T-score between -1.0 and -2.5) who is at least 18 years of age. The
        participant must be willing to undergo an osteogenic loading protocol once per week and/or
        take a pill (placebo or melatonin) for one year. The participant must also be willing to
        come to the study location to receive their monthly capsules and to provide urine, have
        their blood pressure taken and complete questionnaires on 3 occasions (baseline/month 0,
        month 3 and month 12). The study participants must also be willing to get a DXA scan at
        months 0 and 12 at one of the three Weinstein Imaging locations.

        Exclusion criteria: Women or men with osteoporosis; women or men with osteopenia due to
        hyperparathyroidism, multiple myeloma, metastatic bone disease, chronic steroid use
        including corticosteroids; women or men who are on any bone therapies (i.e.
        bisphosphonates, SERMs, hormone therapy, teriparatide, and denosumab); men and women with
        COPD; women or men who smoke; pregnant women; and men or women with muscular dystrophy,
        unmedicated hypertension, or unrepaired hernia, restrictions to movement and exercise, and
        parathyroid dysfunctions.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paula Witt-Enderby, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duquesne University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paula Witt-Enderby, PhD</last_name>
    <phone>412-818-7346</phone>
    <email>Wittp@duq.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ryan Lynch</last_name>
    <phone>412-207-8796</phone>
    <email>Pittsburgh@osteostrong.me</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>OsteoStrong® in Scott Towne Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15220</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ryan Lynch</last_name>
      <phone>412-207-8796</phone>
      <email>Pittsburgh@osteostrong.me</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Duquesne University</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15282</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paula Witt-Enderby, PhD</last_name>
      <phone>412-818-7346</phone>
      <email>wittp@duq.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>January 15, 2020</study_first_submitted>
  <study_first_submitted_qc>January 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2020</study_first_posted>
  <last_update_submitted>June 24, 2020</last_update_submitted>
  <last_update_submitted_qc>June 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bone Diseases, Metabolic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melatonin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

